Desmoid Tumor

Oncology
5
Pipeline Programs
1
Companies
5
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

SpringWorks Therapeutics
OGSIVEOApproved
nirogacestat
SpringWorks Therapeutics
Gamma Secretase Inhibitor [EPC]oral2023

Competitive Landscape

1 companies ranked by most advanced pipeline stage

SpringWorks Therapeutics
5 programs
2
1
1
NirogacestatPhase 4Small Molecule1 trial
Nirogacestat oral tabletPhase 31 trial
NirogacestatPhase 2Small Molecule1 trial
Nirogacestat oral tabletPhase 21 trial
NirogacestatN/ASmall Molecule1 trial
Active Trials
NCT05041036Available
NCT05949099RecruitingEst. Feb 2028
NCT07170644Recruiting18Est. Dec 2030
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SpringWorks TherapeuticsNirogacestat
SpringWorks TherapeuticsNirogacestat oral tablet
SpringWorks TherapeuticsNirogacestat oral tablet
SpringWorks TherapeuticsNirogacestat

Clinical Trials (5)

Total enrollment: 210 patients across 5 trials

NCT07176689SpringWorks TherapeuticsNirogacestat

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Start: Sep 2025Est. completion: Mar 203150 patients
Phase 4Recruiting
NCT03785964SpringWorks TherapeuticsNirogacestat oral tablet

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Start: Apr 2019Est. completion: Oct 2024142 patients
Phase 3Completed
NCT07170644SpringWorks TherapeuticsNirogacestat oral tablet

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Start: Aug 2025Est. completion: Dec 203018 patients
Phase 2Recruiting
NCT05949099SpringWorks TherapeuticsNirogacestat

Study of Cryoablation and Nirogacestat for Desmoid Tumor

Start: Aug 2023Est. completion: Feb 2028
Phase 2Recruiting
NCT05041036SpringWorks TherapeuticsNirogacestat

Individual Patient Compassionate Use of Nirogacestat

N/AAvailable

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 210 patients
Small Molecule is the dominant modality (100% of programs)
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)